RiteMED Co-amoxiclav Dosage/Direction for Use

Doses are expressed throughout in terms of amoxicillin/clavulanic acid content except when doses are stated in terms of an individual component.
The dose of amoxicillin/clavulanic acid that is selected to treat an individual infection should take into account: The expected pathogens and their likely susceptibility to antibacterial agents (see Precautions).
The severity and the site of the infection.
The age, weight and renal function of the patient as shown as follows.
The use of alternative presentations of amoxicillin/clavulanic acid (e.g. those that provide higher doses of amoxicillin and/or different ratios of amoxicillin to clavulanic acid) should be considered as necessary (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Elderly: No dose adjustment is considered necessary.
Hepatic impairment: Dose with caution and monitor hepatic function at regular intervals (see Contraindications and Precautions).
625 mg: For adults and children ≥40 kg, this formulation of co-amoxiclav provides a total daily dose of 1500 mg amoxicillin/375 mg clavulanic acid, when administered as recommended as follows.  For children <40 kg, this formulation of co-amoxiclav provides a maximum daily dose of 2400 mg amoxicillin/600 mg clavulanic acid, when administered as recommended as follows. If it is considered that a higher daily dose of amoxicillin is required, it is recommended that another preparation of co-amoxiclav is selected in order to avoid administration of unnecessary high daily doses of clavulanic acid (see Precautions regarding prolonged therapy).
Adults and children ≥40 kg: One 500 mg/125 mg dose taken three times a day.
Children <40 kg: 20 mg/5 mg/kg/day to 60 mg/15 mg/kg/day given in three divided doses.
Children may be treated with co-amoxiclav tablets, suspensions or pediatric sachets.
Children aged 6 years and below should preferably be treated with co-amoxiclav suspension or pediatric sachets.
No clinical data are available on doses of co-amoxiclav 4:1 formulations higher than 40 mg/10 mg/kg per day in children under 2 years.
Renal impairment: Dose adjustments are based on the maximum recommended level of amoxicillin.
No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 mL/min.
Method of administration: Co-amoxiclav is for oral use. Administer at the start of a meal to minimize potential gastrointestinal intolerance and optimize absorption of amoxicillin/clavulanic acid.
1 g: For adults and children ≥40 kg, this formulation of amoxicillin/clavulanic acid provides a total daily dose of 1,750 mg amoxicillin/250 mg clavulanic acid with twice daily dosing and 2,625 mg amoxicillin/375 mg clavulanic acid with three times daily dosing, when administered as recommended as follows. 
For children <40 kg, using other formulations of amoxicillin/clavulanic acid, a maximum daily dose of 1,000-2,800 mg amoxicillin/143-400 mg clavulanic acid can be provided, when administered as recommended as follows. If it is considered that a higher daily dose of amoxicillin is required, it is recommended that adequate preparations of amoxicillin/clavulanic acid are selected in order to avoid administration of unnecessarily high daily doses of clavulanic acid (see Precautions and Pharmacology: Pharmacodynamics under Actions).
The duration of therapy should be determined by the response of the patient. Some infections (e.g. osteomyelitis) require longer periods of treatment. Treatment should not be extended beyond 14 days without review (see Precautions regarding prolonged therapy).
Adults and children ≥40 kg: Recommended doses: standard dose: (for all indications) 875 mg/125 mg two times a day.
Higher dose: (particularly for infections such as otitis media, sinusitis, lower respiratory tract infections and urinary tract infections): 875 mg/125 mg three times a day.
Children <40 kg: Children may be treated with amoxicillin/clavulanic acid tablets, suspensions or paediatric sachets.
Recommended doses: 25 mg/3.6 mg/kg/day to 45 mg/6.4 mg/kg/day given as two divided doses; up to 70 mg/10 mg/kg/day given as two divided doses may be considered for some infections (such as otitis media, sinusitis and lower respiratory tract infections).
The table as follows presents the received dose (mg/kg body weight) in children weighing 25 kg to 40 kg upon administering a single 875 mg/125 mg tablet. (See Table 4.)

Click on icon to see table/diagram/image

Children weighing less than 25 kg should preferably be treated with amoxicillin/clavulanic acid [suspension or paediatric sachets].
No clinical data are available for amoxicillin/clavulanic acid 7:1 formulations regarding doses higher than 45 mg/6.4 mg per kg per day in children under 2 years.
There are no clinical data for amoxicillin/clavulanic acid 7:1 formulations for patients under 2 months of age. Dosing recommendations in this population therefore cannot be made.
Renal impairment: No dose adjustment is required in patients with creatinine clearance (CrCl) greater than 30 mL/min. In patients with creatinine clearance less than 30 mL/min, the use of amoxicillin/clavulanic acid presentations with an amoxicillin to clavulanic acid ratio of 7:1 is not recommended, as no recommendations for dose adjustments are available.
Method of administration: Amoxicillin/clavulanic acid is for oral use.
Administer at the start of a meal to minimise potential gastrointestinal intolerance.
Therapy can be started parenterally according to the SmPC of the IV-formulation and continued with an oral preparation.